Advances in the management of non-seminomatous germ cell tumors during the cisplatin era: A single-institution experience

International Journal of Urology

Volumn 11, Issue 9, 2004, Pages 768-773

  Muramaki, Mototsugu ^a   Hara, Isao ^a   Miyake, Hideaki ^b   Yamada, Yuji ^a   Kawabata, Gaku ^a   Kamidono, Sadao ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HYOGO MEDICAL CENTER FOR ADULTS   (Japan)

Author keywords

Chemotherapy; Long term survival; Non seminomatous germ cell tumor

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; VINBLASTINE;

CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CANCER SURVIVAL; CHRONOLOGY; DATA ANALYSIS; FOLLOW UP; HUMAN; MEDICAL RECORD; NON SEMINOMATOUS GERMINOMA; PATIENT CODING; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; CISPLATIN; FOLLOW-UP STUDIES; GERMINOMA; HUMANS; MALE; NEOPLASM STAGING; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TESTICULAR NEOPLASMS; TREATMENT OUTCOME;

EID: 6344293918     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2004.00889.x     Document Type: Review

References (20)

1. Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N. Engl. J. Med. 1997; 337: 242-53.
2. Toner GC, Neerhut GJ, Schwarz MA et al. The management of testicular cancer in Victoria, 1988-3993. Urology Study Committee of the Victorian Co-operative Oncology Group. Med. J. Aust. 2001; 174: 328-31.
3. Nichols CR. Chemotherapy of disseminated germ cell tumors. World J. Urol. 2001; 19: 82-9.
4. Einhorn LH, Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann. Intern. Med. 1977; 87: 293-8.
5. Hartmann JT, Kuczyk MA, Kollmannsberger C, Kanz L, Bokemeyer C. Future prospects in the chemotherapy of metastatic nonseminomatous testicular germ-cell cancer. World J. Urol. 1999; 17: 324-33.
6. Sweeney C. History of testicular cancer chemotherapy: maximizing efficacy, minimizing toxicity. Semin. Urol. Oncol. 2001; 19: 170-9.
7. International Germ Cell Consensus Classification. A prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J. Clin. Oncol. 1997; 15: 594-603.
8. Japanese Urological Association and The Japanese Society of Pathology. General Role for Clinical and Pathological Studies on Testicular Tumors. Kanehara Publishing, Tokyo, 1997.
9. Gerl A, Clemm C, Schmeller N, Hartenstein R, Lamerz R, Wilmanns W. Advances in the management of metastatic non-seminomatous germ cell tumours during the cisplatin era: a single-institution experience. Br. J. Cancer 1996; 74: 1280-5.
10. Horwich A, Huddart R, Dearnaley D. Markers and management of germ-cell tumours of the testes. Lancet 1998; 352: 1535-8.
11. Sonneveld DJ, Hoekstra HJ, van der Graaf WT et al. Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era. Cancer 2001; 91: 1304-15.
12. Sonneveld DJ, Hoekstra HJ, Van Der Graaf WT, Sluiter WJ, Schraffordt Koops H, Sleijfer DT. The changing distribution of stage in nonseminomatous testicular germ cell tumours, from 1977 to 1996. BJU Int. 1999; 84: 68-74.
13. Buetow SA. Epidemiology of testicular cancer. Epidemiol. Rev. 1995; 17: 433-49.
14. Steyerberg EW, Keizer HJ, Stoter G, Habbema JD. Predictors of residual mass histology following chemotherapy for metastatic non-seminomatous testicular cancer: a quantitative overview of 996 resections. Eur. J. Cancer 1994; 30A: 1231-9.
15. Hendry WF, A'Hern RP, Hetherington JW, Peckham MJ, Dearnaley DP, Horwich A. Para-aortic lymphadenectomy after chemotherapy for metastatic non-seminomatous germ cell tumours: prognostic value and therapeutic benefit. Br. J. Urol. 1993; 71: 208-13.
16. Hansen SW, Daugaard G, Rorth M. Treatment of persistent or relapsing advanced germ cell neoplasms with cisplatin, etoposide and bleomycin. Eur. J. Cancer Clin. Oncol. 1986; 22: 595-9.
17. Pizzocaro G, Piva L, Salvioni R, Zanoni F, Milani A. Cisplatin, etoposide, bleomycin first-line therapy and early resection of residual tumor in far-advanced germinal testis cancer. Cancer 1985; 56: 2411-15.
18. Motzer RJ, Mazumdar M, Bosl GJ, Bajorin DF, Amsterdam A, Vlamis V. High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity. J. Clin. Oncol. 1996; 14: 1098-105.
19. Beyer J, Kramar A, Mandanas R et al. High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J. Clin. Oncol. 1996; 14: 2638-45.
20. Baniel J, Foster RS, Gonin R, Messemer JE, Donohue JP, Einhorn LH. Late relapse of testicular cancer. J. Clin. Oncol. 1995; 13: 1170-6.